Cardiovascular Adverse Events Associated with Bispecific T-cell Engager Therapy | JACC: CardioOncology

0:00Hello. My name is Qin Shao. I'm a professor in the Department of Cardiology at Harbin Medical University Cancer Hospital. Where China's first Cardiology Department was established in 2015. Today, I'd like to discuss an editorial comment co-authored by Dr. Dong Liu, Dr. Yue Li, Dr. Zhiyun Zhang, and Mi. This editorial co-authored two original research papers, a dual-center retrospective co-auth study. Title the Cardiovascular Adverse Events associated with bi-specific T-cell engaging therapy by Dr. Ben Dadaq and colleagues from Brigham and Wimines Hospital. Under research later, title the Cardiovascular Adverse Events following bi-specific T-cell redirecting antibody therapy by Dr. Nouching Actor and colleagues from Northwest University, Faber's School of Medicine.

1:00Dr. Ben Dadaq and colleagues retrospective online the failed 167 patients treated with TCEs, about one quarter having pre-existing cardiovascular disease. They found cumulative incidence of cardiovascular events of 10.4%. Most commonly left of a particular dysfunction, new on-site atrial fibrillation on acute coronary syndrome. Cardiovascular death was rare at 0.4%. baseline coronary artery disease independently conferred a roughly 4-fold increase the cardiovascular risk. On the development of grid 2, or hair series, or icons, during treatment was associated with 2.3-fold hair risk. Patients who experienced the cardiovascular event had nearly a 7-fold hair risk of subsequent all-cause mortality, complementing these findings, Dr. Nouching Actor and colleagues reported

2:04a similar cardiovascular event rate of 12.3% in where 140 patients receiving TCEs. These findings have directed clinical implications. Patients with baseline coronary artery disease weren't throughout pre-treatment cardiovascular assessment and optimization of multiple risk factors. During the early treatment period, particularly when CRS or icons develops, a low-world threshold for cardiac monitoring is appropriate. The association between cardiovascular events and the worst overall survival underscores that timely recognition and measurement may meaningfully impact patients' outcomes. Future perspective studies are needed across newer TCE agents and broader populations, including solid tumors, to refine risk stratification and define evidence-based surveillance strategies.

3:06Overall, TCE therapy has a real-shrink cardiovascular safety profile, but risk is not uniform. Touching monitoring on the management will be key as the use continues to expand. Thank you so much for listening.